This systematic review looked at antibody-drug conjugates, which are a type of cancer treatment, specifically for lung cancer. The analysis included data from 466 trials registered globally between 2001 and 2024. The researchers wanted to understand how the landscape for these treatments has changed over time.
The number of trials has grown significantly. There was only one trial registered in 2001, but by 2024, the number had reached 106. Most of these trials were in early phases of development. The review found that 76 different targets were involved in these studies, with the top 15 targets accounting for about 78% of all trials.
Safety information was limited in the review. The authors noted a risk of interstitial lung disease, which is inflammation of the lungs. The study also highlighted that 85.84% of the trials included biomarkers to help identify patients who might benefit most from the treatment.
The main reason to be careful is that the overall clinical trial landscape for lung cancer remains unclear. The authors advocate for stronger collaboration between different continents and a focus on later-phase trials to improve patient outcomes. Readers should understand that this review describes trends in research rather than proving that a specific drug works for everyone.
